Annual Lung SPORE Workshop (Abstract Submission): Submission #12
Submission information
Submission Number: 12
Submission ID: 110380
Submission UUID: 25f6b7f8-678d-4e5f-8452-ee305fafbbd3
Submission URI: /dctd/lungsporemeeting/abstracts
Submission Update: /dctd/lungsporemeeting/abstracts?token=jJlRNmvOh6gqXAVcCV_s4-zJE8FumTdvGt3YrjzPyQs
Created: Fri, 03/08/2024 - 21:20
Completed: Fri, 03/08/2024 - 21:31
Changed: Fri, 05/10/2024 - 08:51
Remote IP address: 10.208.24.212
Submitted by: Anonymous
Language: English
Is draft: No
Webform: LUNG SPORE Investigator - Abstracts
Submitted to: Annual Lung SPORE Workshop (Abstract Submission)
Michael
Oh
UCLA
Phase I trial of intratumoral administration of autologous CCL21 gene-modified dendritic cells combined with pembrolizumab reveals local and systemic immune activation in advanced NSCLC
First Author
Additional Authors
Session 3: Immuno-oncology
LIU_UCLA_Session 3.docx22.94 KB
No
Approved to be a Poster Presenter
{Empty}
Poster Submission
{Empty}